Orchid Pharma, a Chennai-based pharmaceutical leader, has launched Orchid AMS (Antimicrobial Solutions), a new division focused on combating the growing threat of Antimicrobial Resistance (AMR) in India.
In a press statement on Wednesday, the company informed that this strategic initiative aims to engage with over 3,000 hospitals and healthcare institutions nationwide over the next two to three years, leading efforts to implement effective antimicrobial stewardship programs (AMSPs).
Orchid AMS will drive innovation through cutting-edge products, support programs, and digital solutions, including the introduction of pioneering drugs such as Orblicef (Cefepime Enmetazobactam), Ceftaroline, and Cefiderocol, aimed at reducing AMR. As part of its national outreach, Orchid AMS will conduct educational sessions in 13 major cities, facilitating critical discussions on AMR with healthcare professionals, policymakers, and industry leaders.
Manish Dhanuka, Managing Director of Orchid Pharma, emphasised the company's commitment to addressing the AMR crisis, saying, "The launch of Orchid AMS underscores our dedication to providing innovative solutions that tackle one of the most pressing public health challenges of our time."
